Background: As important players of the innate immune system, Toll-like receptors (TLRs) and their role for tumorigenesis have been in the focus of research. In particular TLR7 is an interesting candidate, as TLR7 agonists are broadly used for the treatment of cutaneous tumors. However, data addressing the baseline expression of TLR7 in both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) on the protein level are lacking, while on the genomic level significantly elevated expression of TLR7 in SCC but not in BCC has been demonstrated.
INTRODUCTION
Over the past years, increasing evidence has been provided that the tumor microenvironment plays a crucial role for tumor surveillance. 1 In this context, Toll-like receptors (TLRs) recognizing microbial components, but also damage-/danger-associated molecular patterns, seem to play an important but not yet a fully elucidated role. On recognition of damage-/danger-associated molecular patterns, which are released from damaged cells but also from cells undergoing malignant transformation, TLRs promote the production of proinflammatory cytokines, activate dendritic cells, and eventually trigger the invasion of immune cells to the tumor area. [1] [2] [3] In the field of skin cancer, TLR7 is one particular interesting candidate for investigation, as imiquimod-a TLR7 agonist-is broadly used for the treatment of basal cell carcinoma (BCC). 4, 5 The mechanisms of action of TLR7 agonists have not been fully elucidated; however, it is reported that TLR agonists initiate Th1 immune response but, moreover, directly inhibit hedgehog signaling, the most important pathway for tumorigenesis of BCC. 6 This antitumor effect of TLR7 activation has also been shown in other cancers, for example, Lu et al 7 demonstrated that topical treatment with imiquimod could elicit significant regression of spontaneous breast cancers in transgenic mice. However, there is also evidence that TLR7 may have protumorigenic effects. [8] [9] [10] In a broad gene expression profiling study, Muehleisen et al 11 investigated the regulation of innate immune genes, among them also TLRs and found that squamous cell carcinoma (SCC) but not BCC showed significantly elevated expression of TLR7. As TLRs are, however, not only regulated on transcriptional but also on protein level, we sought to profile TLR7 expression in SCC and BCC on protein level and answer the question if the baseline expression of TLR7 could be helpful in distinguishing BCC from SCC solely based on the TLR7 immunohistochemical staining pattern. In the case of a clear distinct TLR7 signature, one could imagine using TLR7 as a marker to categorize basosquamous carcinoma (BSC), a tumor entity showing characteristics of both SCC and BCC and thus, are challenging in correct diagnosis. 12 Besides, we aimed to correlate TLR7 staining with the grade of tumor differentiation in SCC as an indirect marker of tumor progress.
MATERIALS AND METHODS

Epidemiologic Data
This research comprised tissue of 51 patients (32 men and 19 women). The average age was 77 years (range 46-98 years). The samples investigated consisted of 24 SCC graded by the classification of Broder 13 into grade G1, G2, and G3 (denoted according to the ratio of differentiated to undifferentiated cells of 3:1, 1:1, and 1:3) and of 23 BCC, divided into the histopathological subtypes "superficial" (n = 9), "sclerodermiform" (n = 6), "solid" (n = 8), and 4 BSC.
Histopathological Evaluation
All samples were obtained from the Department of Dermatology and Allergy of the Technical University of Munich, Germany. Paraffin-embedded tissue was selected from our histopathological archive comprising SCC (n = 24), BSC (n = 4), and BCC (n = 23). Sections underwent routine hematoxylin/eosin staining, and histopathological diagnostics was performed by 2 independent histopathologists. SCCs were subclassified into 3 groups according to their grade of differentiation (Broders, G1-G3) and BCC into 4 diagnostic subgroups (see above). The diagnosis of BSC was made when tumors showed intermediate criteria in their differentiation toward BCC or SCC according to the classification of Weedon. 14 In contrast to pure BCC, the basaloid cells in BSC partly showed eosinophilic cytoplasm, often lacked the characteristic peripheral palisading and retraction artifact and exhibited variable cytoplasmic keratinization.
Immunohistochemistry
Sections were dewaxed and rehydrated. Stainings were performed by an automated BOND system (Leica) according to the manufacturer's instructions: after antigen retrieval in a pH 6 citrate buffer-based epitope retrieval solution (Leica), sections were incubated with a monoclonal antibody against TLR7 (rabbit anti-TLR7; Abcam), followed by subsequent application of a secondary polymeric alkaline phosphataselinked anti-rabbit antibody. The complex was visualized by the substrate chromogen Fast Red. Eventually, slides were counterstained with hematoxylin. As a negative control, primary antibodies were replaced with an irrelevant isotypematched monoclonal antibody. Each section was fully investigated by 2 masked investigators for TLR7 staining in tumor center, tumor margin, peritumoral infiltrate, and adnexae. Positive infiltrates were evaluated on a quantitative scale ranging from "no staining" (2) to triple-positive staining (+++), the cutoff values were +: 5%-10%, ++: 10%-30%, and +++: 30%-50%. This categorization was chosen as there was no TLR7 staining within the inflammatory infiltrate in the range of ,5% or .50%.
Immunofluorescence
The dewaxed and rehydrated sections from the paraffinembedded blocks underwent antigen retrieval in a pressure cooker with boiling citrate buffer, pH = 6. After a blocking step with 10% normal goat serum and 10% normal donkey, a mix of TLR7 (rabbit anti-TLR7; Abcam) and a second primary antibody (mouse anti-CD2, Cellmarque, mouse anti-cytokeratin AE1 and AE2; Zytomed Systems, respectively) was applied for 1 hour at room temperature and then overnight. Subsequently, incubation with secondary antibody mix (488 goat-anti-rabbit antibody; Life Technologies, and 557 donkey anti-mouse antibody; R&D Systems, 1:500) was performed in the dark for 1 hour. To quench autofluorescence, sections were incubated in 0.1% Sudan Black B solution, diluted in 70% ethanol followed by a washing step with 0.02% Tween 20 diluted in PBS and several changes of dH 2 O. Before mounting the sections (Vectashield Mounting Medium, Burlingame, CA), incubation with DAPI for 
RESULTS
Within the group of BSC (n = 4), we found 1 sample weakly positive for immune cells at the tumor center but strongly positive for TLR7 expression in the peritumoral immunocellular infiltrate, whereas 2 samples only showed peritumoral reactivity and 1 sample was completely negative for TLR7 in all sections ( Table 1) .
Seven of 23 BCC showed variable intensity of TLR7 staining of the peritumoral and adnexal infiltrate (30.4%), and 3 of these 7 samples also showed weak TLR7 reactivity of immune cells in the tumor center and/or tumor margin ( Table 1) . Sixteen of 23 BCC (69.6%) did not show any positivity for TLR7. The analysis of the different subtypes of BCC (solid, sclerodermiform, and superficial) did not show differences of TLR7 expression.
In contrast to the group of BCC, 45.8% of the SCC (n = 24) were positive for TLR7 (Table 1 ). Detailed analysis revealed that the percentage of TLR7 positivity correlated with the grade of tumor differentiation. Among the welldifferentiated SCC (G1), 11 of 15 (73.33%) samples showed either strong tumoral or peritumoral immunocellular reactivity (Fig. 1) , whereas the lower differentiated SCC (G2-G3)-apart from 1 sample (11.1%)-showed no TLR7 expression of the peritumoral/periadnexal infiltrate. To gain further insights concerning TLR7 expression within the tumoral and/or peritumoral area, we performed immunofluorescence double staining of CD2, a marker for T cells and natural killer cells as major cellular players of the tumor microenvironment, as well as of AE1 and AE2, a marker for cytokeratin in SCC, and TLR7. We confirmed that TLR7 expression was exclusively expressed by immune cells of the peritumoral and tumoral infiltrate but not by the tumor tissue itself (Fig. 2B) . Besides, we found that the TLR7-positive immune cells of the peritumoral infiltrate were in close interaction with CD2 positive cells which themselves did not express TLR7.
DISCUSSION
In our study, we sought to compare the immunohistochemical staining patterns of TLR7 in the malignant epithelial tumors SCC, BCC, and BSC for the sake of establishing a marker for the differentiation of intermediate cancer types such as BSC.
We found TLR7 staining in both BCC and SCC, regarding the tumoral and peritumoral immunocellular infiltrate, with a slightly higher percentage of TLR7-positive immune cells in SCC (45.8% of all SCC) than TLR7-positive immune cells in BCC (30.4% of all BCC). As confirmed by immunofluorescence double staining, the tumor cells themselves did not express TLR7, but exclusively immune cells of the peritumoral and tumoral infiltrate. Whereas on mRNA level, TLR7 expression in SCC was shown to be more than a dozen fold higher than that in BCC, 11 these antipodal results could not be reproduced on the protein level and thus did not allow categorization of BCC and SCC by the "TLR7-fingerprint" only.
However, when looking at the differentiation status of SCC, we found that the well-differentiated SCCs show strong TLR7 staining in the tumoral and/or peritumoral immunocellular infiltrate in contrast to the less differentiated SCCs. As shown by immunofluorescence double staining, we demonstrated that TLR7 expressing immune cells were in close interaction with CD2-positive T cells and natural killer cells suggesting that TLR7 expression may be positively associated with tumor control implying a potentially stronger antigen-specific adaptive immune response mediated through increased invasion of TLR7-positive immune cells in the higher differentiated SCC. Recently, Ni et al 15 demonstrated that a high expression of TLR7 in peritumoral fibroblast-like cells and low expression in the tumor center of oral SCCs correlated with a better differentiation and longer survival time compared with those with an expression pattern viceversa. With our study, we confirmed that TLR7 staining in SCC positively correlated with a better differentiation status of SCC regarding the peritumoral immunocellular infiltrate. As poor differentiation grade of SCC was shown to correlate with a poor prognosis, 16 one may speculate that TLR7 staining in immune cells of tumor center and tumor margin correlates with a better prognosis. In the case of BCC, one may hypothesize that therapy with imiquimod may be in particular effective in those BCC showing a strong TLR7-positive immunocellular infiltrate already at baseline level which might provide a fast and effective inflammatory response to control the tumor. However, further prospective studies with higher numbers of patients including a detailed clinical follow-up of the patients would be needed to correlate TLR7 staining pattern with therapeutic outcome and recurrence rates in both BCC and SCC. In summary, our study implies a rather antitumorigenic than protumorigenic effect of TLR7 and, thus, adds another puzzle piece within the discussion on the ambiguous role of TLRs for tumor progression. To our knowledge, this is the first study explicitly investigating TLR7 expression in BCC and SCC on the protein level.
